Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Epirus Biopharmaceuticals Company Profile (NASDAQ:EPRS)

Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:EPRS) (?)
Ratings Breakdown: 2 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $6.60 (31.21% upside)

Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Show:
DateFirmActionRatingPrice TargetDetailsShare
10/6/2014Leerink SwannInitiated CoverageOutperform$12.00ViewTweet This Rating  Share This Rating on StockTwits
11/12/2013WedbushDowngradeOutperform -> Neutral$1.20ViewTweet This Rating  Share This Rating on StockTwits
11/11/2013OppenheimerDowngradeOutperform -> Market PerformViewTweet This Rating  Share This Rating on StockTwits
3/7/2013MLV & Co Boost Price TargetHold$0.50 -> $0.75ViewTweet This Rating  Share This Rating on StockTwits
3/6/2013OppenheimerReiterated RatingOutperform$2.00ViewTweet This Rating  Share This Rating on StockTwits
1/3/2013Piper JaffrayInitiated CoverageNeutralViewTweet This Rating  Share This Rating on StockTwits
(Data available from 10/23/2012 forward)
Discuss Epirus Biopharmaceuticals